BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27267070)

  • 1. Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines.
    Mokaddas E; Albert MJ
    Expert Rev Vaccines; 2016 Oct; 15(10):1337-45. PubMed ID: 27267070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.
    Imöhl M; Reinert RR; van der Linden M
    Int J Med Microbiol; 2015 Oct; 305(7):776-83. PubMed ID: 26324014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines.
    Koutouzis EI; Michos A; Koutouzi FI; Chatzichristou P; Parpounas K; Georgaki A; Theodoridou M; Tsakris A; Syriopoulou VP
    Pediatr Infect Dis J; 2016 Mar; 35(3):292-6. PubMed ID: 26569193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study.
    Charfi F; Smaoui H; Kechrid A
    Vaccine; 2012 Dec; 30 Suppl 6():G18-24. PubMed ID: 23228353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of penicillin non-susceptible Streptococcus pneumoniae isolated before and after pneumococcal conjugate vaccine implementation in Casablanca, Morocco.
    Diawara I; Barguigua A; Katfy K; Nayme K; Belabbes H; Timinouni M; Zerouali K; Elmdaghri N
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):23. PubMed ID: 28376809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period.
    Okade H; Funatsu T; Eto M; Furuya Y; Mizunaga S; Nomura N; Mitsuyama J; Yamagishi Y; Mikamo H
    J Infect Chemother; 2014 Jul; 20(7):423-8. PubMed ID: 24802765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.
    van der Linden M; Perniciaro S; Imöhl M
    BMC Infect Dis; 2015 May; 15():207. PubMed ID: 25940580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.
    Mokaddas E; Syed S; Albert MJ
    Hum Vaccin Immunother; 2021 Nov; 17(11):4661-4666. PubMed ID: 34435932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
    Allemann A; Frey PM; Brugger SD; Hilty M
    Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.